Moderna and Merck shares soar on mRNA cancer vaccine
AI Summary
Moderna and Merck shares jumped following news that their personalized mRNA treatment successfully prevented skin cancer from recurring or spreading in a late-stage trial. This breakthrough is significant as it comes amid a controversial debate about mRNA technology's risks and benefits, especially after federal funding cuts by Trump administration officials. If successful, the therapy could revolutionize cancer treatment and solidify mRNA's place in medical innovation.
Original Source
Read the full article at Axios →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.